
2. What is the prevalence of Obstructive Sleep Apnoea verses Central Sleep Apnoea and the role of Software Monitoring Solutions

In blog 1 of these series, we explored why it's important for Sleep Medicine Clinicians to differentiate between Obstructive Sleep Apnoea (OSA) and Central Sleep apnoeas (CSA) and Hypopnoeas? In this 2nd blog we will explore recent understanding of OSA and CSA reported prevalence, software management methods of detection of these events and tailoring treatment parameters based on remote monitoring data.



CSA and OSA are two different types of sleep apnea with varying prevalence: Obstructive Sleep Apnea Central Sleep Apnea

1. OSA is thought to affect up to 1 billion people globally and is a frequent condition marked by recurrent instances of partial or total blockage of the upper airway during sleep, resulting in diminished or halted airflow. The estimated prevalence of OSA in the general population ranges from approximately 9% to 38%, with variations influenced by factors such as age, sex, and obesity 1-2.

2. CSA is less common compared to OSA. It occurs when the brain fails to send the appropriate signals to the muscles that control breathing. The prevalence is lower, and is estimated to affect 5-10% of the general population, but it is more common in individuals with certain conditions such as heart failure or those using certain medications 3.

The prevalence of CSA can be higher in certain populations.

Central sleep apnea (CSA) is when there is a reduction or cessation in breathing during sleep due to the brain failing to signal the body to breathe. Here's an overview of the different forms:

1. CSA with Cheyne–Stokes Breathing (CSB): Often linked with heart failure, this type involves a pattern of breathing where periods of deep breaths alternate with shallow or no breaths. This fluctuation is caused by delayed respiratory system feedback, occurring frequently in individuals with heart problems.

2. CSA due to a Medical Disorder without CSB: This form results from other medical conditions that don't show the Cheyne-Stokes pattern. Conditions such as neurological disorders, including brainstem lesions or strokes, can affect the brain's ability to manage breathing during sleep.

3. CSA due to High-Altitude Periodic Breathing: At high altitudes, lower oxygen availability can lead to periodic breathing changes. This results in cycles of over breathing followed by pauses in breathing due to altered brain control.

4. CSA due to a Medication or Substance: Certain drugs, particularly those impacting the central nervous system like opioids, can suppress the drive to breathe. This disruption in normal breathing regulation because of medication effects can lead to CSA.

5. Treatment-Emergent CSA (TE-CSA): This arises when someone treated for obstructive sleep apnea develops central sleep apnea during their therapy, typically with positive airway pressure (PAP). Initially, obstructive events occur, but central apneas may develop as these are treated.

These distinct but often overlapping phenotypes may require diagnostic strategies and treatment plans based on their specific characteristics and underlying causes 3-4.

Symptoms of Central Sleep Apnea

- Difficulty concentrating
- Frequent awakenings during the night
- Shortness of breath upon waking
- Insomnia (difficulty staying asleep)

- Excessive daytime sleepiness
- Mood changes
- Morning headaches

Detection of CSA is challenging due to several factors:

1. Symptom Overlap: CSA shares symptoms with obstructive sleep apnea (OSA), such as daytime sleepiness and snoring, leading to potential misdiagnosis.

2. Intermittent Nature: CSA can occur sporadically during sleep, making it difficult to capture in a single sleep study.

3. Complex Diagnosis: Diagnosis requires overnight polysomnography (PSG), which is costly with long waiting times and logistically challenging. Home tests typically lack sufficient monitoring for CSA.

4. Clinical Awareness : Healthcare providers may be less familiar with CSA, leading to underdiagnosis or misdiagnosis.

5. Coexisting Conditions: CSA often occurs with other health issues, complicating evaluation and understanding the underlying cause.

6. Variation in Responses: Different patients may respond variably to treatment, necessitating trial-and-error approaches.

7. Limited Access to Specialists: Availability of sleep specialists can be restricted, delaying diagnosis and treatment.

The diagnosis of CSA requires careful evaluation, highlighting the need for collaboration between sleep specialists and the wider multi-disciplinary team to improve patient outcomes 3.

Role of Management Software in Sleep Apnea - Sefam Connect V 2.9

0	Murphie Phyllis	< Marina Forbes ?						
9	Profile U Sign out	Patient Night calendar	Treatment evolution profile	Connected dev	ices P	ostponement	Remote settings	Detailed charts
		Usage duration (ON/OFF) (h/d) / Period	8 h 0 min/d					01 02 03 04 05 06 02 04 59 10 (11
	Patients	Useful duration (h/d) / Period	7 h 54 min/d Kill	05/29/2024				
7		Avg. Time in Ramp (H/D)	0 h 46 min/d My	05/27/2024			and the second se	IN DATES AND ADD AT 18
	Devices	Days without utilization	4 x Sur	05/26/2024			2.10(11)20(2)	1 27 00 30 10 1
	-T-04/76/76	Days of usage < 4 (hid)	4 x Sat	05/25/2024				
Ö.	Settings history	Days of usage >= 4 (h/d)	92 % Fri	05/24/2024				\$7.00 39.10 T
		Mask disconnected	100	05/23/2024			and the second se	17 02 12 04 04 00 12 00 19 10 10
	Doctors	Total number of sessions ON/OFF	100 Kill				2111 201 21 22 22 22	24.32 14.32
1	-700000870	UNINTENTIONAL LEAK	My	05/20/2024			2,10,225,20	1 17 44 22 14 21
2	Analysis parameters	Avg	13 1/min Sur	05/19/2024			211,32,1	AND A DEAL OF THE AVERAGE AND
		Min	Sal	05/18/2024	• • •			14 M 10 M 10 M
0	Users roles	Max	47 1/510 Fri	05/17/2024 05/16/2024				
2		% of time > limit leak	2.0 X We					10 77 88 54 76 64 88 54 88 14 18
			2.0 x	AT ATTACANT STATES				15, 65 E7 03 28 10 (t)
0	Collapse menu	DETECTED EVENTS INDEX	My	05/13/2024			1 18 11 24 2 200	To an a first of the second second
		Total AHI	3.2 evts/h Sur					\$7, 44 305 to 33
		Obstructive AHI	2.6 evts/h Sat	05/11/2024				1 CE 17 CA 337 1A 15
		Obstructive apneas	2.3 evts/h Fri	05/10/2024 05/09/2024			and the second	12 c3 (0) 15 (1)
		Obstructive hypopneas	0.3 evts/h Thu	05/08/2024				CJ 39 15 31
		Central AHI	0.5 evts/h Kill				2 15 18 26 26 27 18 00	22 44 UK 14 W
IR	User manual	Central apneas	0.5 evts/h My	05/06/2024			Intell [®] - Different and the	1 27 01 35 10 11
	Ceol manual	Central hypopneas	0.0 evts/h Sur	05/05/2024			1111120120101	100 A 100 A 100 A 100 A

Management software plays a pivotal role in the ongoing treatment and monitoring of treatment efficacy by equipping Sleep medicine clinicians and their patients with innovative software and apps to have oversight of therapy and optimise treatment plans.

With features such as real-time data collection from CPAP/APAP devices these software solutions enable precise tracking of sleep patterns, apnoea events, mask leakage and therapy adherence. This facilitates the early detection of treatment issues, enhances patient compliance through timely reminders and alerts, and provides comprehensive data analysis for clinicians to tailor treatment strategies. Telemonitoring software helps improve patient therapy adherence, is cost effective and supports more effective and personalised care for people with sleep apnoea 5-6. reduce words here.

Differentiating between OSA and CSA is vital for accurate diagnosis and effective management. While OSA is more prevalent, CSA presents various phenotypes that complicate assessment.

Advancements in management software are transforming how sleep apnea is monitored and treated. These tools enable real-time data tracking, enhance patient compliance, and allow for personalised treatment plans. By leveraging technology, we can significantly enhance the quality of life for those with these disorders.

In blog 3 of these series, we will share the findings of a large "Real World Study" about why failing to distinguish between central and obstructive hypopneas may lead to an underestimation of the severity of CSA which may misguide treatment choices.

1. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis - PubMed (nih.gov)

- 2. <u>Prevalence of obstructive sleep apnea in the general population: A systematic</u> <u>review - PubMed (nih.gov)</u>
- 3. Central sleep apnoea: not just one phenotype (ersjournals.com)
- 4. Rules for Scoring Respiratory Events in Sleep: Update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events: Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine: Journal of Clinical Sleep Medicine: Vol 08, No 05
- 5. <u>Remote consulting with telemonitoring of continuous positive airway pressure</u> <u>usage data for the routine review of people with obstructive sleep apnoea</u> <u>hypopnoea syndrome: A systematic review - PubMed (nih.gov)</u>
- 6. <u>Virtual consultations for patients with obstructive sleep apnoea: a systematic</u> review and meta-analysis | European Respiratory Society (ersjournals.com)